​

MiMedx Group, Inc.

NasdaqCM:MDXG Stock Report

Market Cap: US$935.0m

MiMedx Group (MDXG) Stock Overview

Develops and distributes placental tissue allografts for various sectors of healthcare. More details

MDXG fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 70.4% below our estimate of its fair value

Earnings are forecast to grow 14.85% per year

Analysts in good agreement that stock price will rise by 78.8%

Risk Analysis

Profit margins (11.3%) are lower than last year (20.5%)


MDXG Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

MDXG logo
MiMedx Group
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 4 Analysts

EpiFix's Japanese Success And HELIOGEN Adoption Will Strengthen Future Prospects

Key Takeaways MiMedx anticipates increased revenue and market share through the implementation of pending LCDs and product innovation in HELIOGEN. International expansion and innovations like EpiFix and MiMedx Connect are crucial for enhancing revenue, margins, and customer relationships.
View narrative
US$13.04
FV
48.5% undervalued intrinsic discount
9.64%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
about 18 hours ago author updated this narrative
View MiMedx Group Community

MiMedx Group, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for MiMedx Group
Historical stock prices
Current Share PriceUS$6.71
52 Week HighUS$10.14
52 Week LowUS$5.47
Beta1.76
1 Month Change12.02%
3 Month Change0.45%
1 Year Change-10.05%
3 Year Change90.09%
5 Year Change23.35%
Change since IPO31.57%

Recent News & Updates

MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt

Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt

Recent updates

MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt

Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt

Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio

Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio

MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly

Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly

Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings

Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings

Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors

Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors

We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
author-image

HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges

The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27
Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18
MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Aug 08
Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Apr 22
Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

Dec 20
Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

Shareholder Returns

MDXGUS BiotechsUS Market
7D-3.6%-0.3%-0.09%
1Y-10.1%-12.0%12.4%

Return vs Industry: MDXG exceeded the US Biotechs industry which returned -14.8% over the past year.

Return vs Market: MDXG underperformed the US Market which returned 10% over the past year.

Price Volatility

Is MDXG's price volatile compared to industry and market?
MDXG volatility
MDXG Average Weekly Movement6.5%
Biotechs Industry Average Movement11.4%
Market Average Movement6.4%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: MDXG has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MDXG's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006837Joe Capperwww.mimedx.com

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.

MiMedx Group, Inc. Fundamentals Summary

How do MiMedx Group's earnings and revenue compare to its market cap?
MDXG fundamental statistics
Market capUS$934.95m
Earnings (TTM)US$39.96m
Revenue (TTM)US$352.38m
24.8x
P/E Ratio
2.8x
P/S Ratio

Is MDXG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDXG income statement (TTM)
RevenueUS$352.38m
Cost of RevenueUS$63.64m
Gross ProfitUS$288.73m
Other ExpensesUS$248.77m
EarningsUS$39.96m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 30, 2025

Earnings per share (EPS)0.27
Gross Margin81.94%
Net Profit Margin11.34%
Debt/Equity Ratio9.2%

How did MDXG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/16 13:18
End of Day Share Price 2025/07/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MiMedx Group, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesBrean Capital
William PlovanicCanaccord Genuity
Ross OsbornCantor Fitzgerald & Co.